HARVARD BIOSCIENCE INC — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO John Duke and CFO Mark Frost certified Harvard Bioscience's Q2 2026 10-Q on August 11, 2026. Both officers attested that the financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certification boilerplate. Absence of control deficiencies is positive but expected; lacks substantive business or financial disclosure.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.